The Library
Competing treatments for migraine : a headache for decision-makers
Tools
Mistry, Hema, Naghdi, Seyran, Underwood, Martin, Duncan, Callum, Madan, Jason and Matharu, Manjit (2023) Competing treatments for migraine : a headache for decision-makers. The Journal of Headache and Pain, 24 (1). 162. doi:10.1186/s10194-023-01686-y ISSN 1129-2377.
|
PDF
s10194-023-01686-y.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1225Kb) | Preview |
Official URL: https://doi.org/10.1186/s10194-023-01686-y
Abstract
Background: Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for Health and Care Excellence. Aim: To assess the cost-effectiveness of drugs used to treat adults with chronic migraine. Methods: We did a systematic review of placebo-controlled trials of preventive drugs for chronic migraine. We then assessed the cost-effectiveness of the currently prescribable drugs included in the review: Onabotulinum toxin A (BTA), Eptinezumab (100mg or 300mg), Fremanezumab (monthly or quarterly dose), Galcanezumab or Topiramate, each compared to placebo, and we evaluated them jointly. We developed a Markov (state-transition) model with a three-month cycle length to estimate the costs and quality-adjusted life years (QALYs) for the different medications from a UK NHS and Personal Social Services perspective. We used a two-year time horizon with a starting age of 30 years for the patient cohort. We estimated transition probabilities based on monthly headache days using a network meta-analysis (NMA) developed by us, and from published literature. We obtained costs from published sources and applied discount rates of 3.5% to both costs and outcomes. Results: Deterministic results suggest Topiramate was the least costly option and generated slightly more QALYs than the placebo, whereas Eptinezumab 300mg was the more costly option and generated the most QALYs. After excluding dominated options, the incremental cost-effectiveness ratio (ICER) between BTA and Topiramate was £68,000 per QALY gained and the ICER between Eptinezumab 300mg and BTA was not within plausible cost-effectiveness thresholds. The cost-effectiveness acceptability frontier showed that Topiramate is the most cost-effective medication for any amount the decision maker is willing-to-pay per QALY. Conclusions: Among the various prophylactic medications for managing chronic migraine, only Topiramate was within typical cost-effectiveness threshold ranges. Further research is needed, ideally an economic evaluation alongside a randomised trial, to compare these newer, expensive CGRP MAbs with the cheaper oral medications.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine | ||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||
SWORD Depositor: | Library Publications Router | ||||||
Library of Congress Subject Headings (LCSH): | Migraine -- Treatment, Headache -- Treatment, Migraine -- Diagnosis | ||||||
Journal or Publication Title: | The Journal of Headache and Pain | ||||||
Publisher: | Springer Milan | ||||||
ISSN: | 1129-2377 | ||||||
Official Date: | 5 December 2023 | ||||||
Dates: |
|
||||||
Volume: | 24 | ||||||
Number: | 1 | ||||||
Article Number: | 162 | ||||||
DOI: | 10.1186/s10194-023-01686-y | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||
Date of first compliant deposit: | 7 December 2023 | ||||||
Date of first compliant Open Access: | 7 December 2023 | ||||||
RIOXX Funder/Project Grant: |
|
||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year